Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew B West

Showing results (1-10 of 115) with videos related to

Pageof 12
Sort By:
Movement Disorders : Official Journal of the Movement Disorder Society|December 3, 2014
Ten years and counting: moving leucine-rich repeat kinase 2 inhibitors to the clinicAndrew B West
Experimental Neurology|August 3, 2017
Achieving neuroprotection with LRRK2 kinase inhibitors in Parkinson diseaseAndrew B West
Genome Medicine|October 21, 2017
Breathing new life into an old target: pulmonary disease drugs for Parkinson's disease therapyHisham Abdelmotilib, Andrew B West
Frontiers in Neuroscience|September 9, 2020
Pharmacodynamic Biomarkers for Emerging LRRK2 TherapeuticsKaela Kelly, Andrew B West
Biochemical Society Transactions|March 7, 2019
Caught in the act: LRRK2 in exosomesShijie Wang, Andrew B West
Biochimica Et Biophysica Acta. Proteins and Proteomics|December 13, 2016
The dual enzyme LRRK2 hydrolyzes GTP in both its GTPase and kinase domains in vitroZhiyong Liu, Andrew B West
Antioxidants & Redox Signaling|March 11, 2009
The therapeutic potential of LRRK2 and alpha-synuclein in Parkinson's diseaseSaurabh Sen, Andrew B West
Biochimica Et Biophysica Acta|November 1, 2008
Zeroing in on LRRK2-linked pathogenic mechanisms in Parkinson's diseaseSaskia Biskup, Andrew B West
Biochemical Society Transactions|April 4, 2023
The interplay between monocytes, α-synuclein and LRRK2 in Parkinson's diseaseSamuel Strader, Andrew B West
Movement Disorders : Official Journal of the Movement Disorder Society|April 30, 2016
Identification of bona-fide LRRK2 kinase substratesAndrew B West, Mark R Cookson
Pageof 12

Showing results (1-10 of 115) with videos related to

Sort By:
Pageof 12
Movement Disorders : Official Journal of the Movement Disorder Society|December 3, 2014
Ten years and counting: moving leucine-rich repeat kinase 2 inhibitors to the clinicAndrew B West
Experimental Neurology|August 3, 2017
Achieving neuroprotection with LRRK2 kinase inhibitors in Parkinson diseaseAndrew B West
Genome Medicine|October 21, 2017
Breathing new life into an old target: pulmonary disease drugs for Parkinson's disease therapyHisham Abdelmotilib, Andrew B West
Frontiers in Neuroscience|September 9, 2020
Pharmacodynamic Biomarkers for Emerging LRRK2 TherapeuticsKaela Kelly, Andrew B West
Biochemical Society Transactions|March 7, 2019
Caught in the act: LRRK2 in exosomesShijie Wang, Andrew B West
Biochimica Et Biophysica Acta. Proteins and Proteomics|December 13, 2016
The dual enzyme LRRK2 hydrolyzes GTP in both its GTPase and kinase domains in vitroZhiyong Liu, Andrew B West
Antioxidants & Redox Signaling|March 11, 2009
The therapeutic potential of LRRK2 and alpha-synuclein in Parkinson's diseaseSaurabh Sen, Andrew B West
Biochimica Et Biophysica Acta|November 1, 2008
Zeroing in on LRRK2-linked pathogenic mechanisms in Parkinson's diseaseSaskia Biskup, Andrew B West
Biochemical Society Transactions|April 4, 2023
The interplay between monocytes, α-synuclein and LRRK2 in Parkinson's diseaseSamuel Strader, Andrew B West
Movement Disorders : Official Journal of the Movement Disorder Society|April 30, 2016
Identification of bona-fide LRRK2 kinase substratesAndrew B West, Mark R Cookson
Pageof 12